首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   879711篇
  免费   73615篇
  国内免费   3362篇
耳鼻咽喉   12892篇
儿科学   24854篇
妇产科学   25236篇
基础医学   126005篇
口腔科学   25835篇
临床医学   77691篇
内科学   167013篇
皮肤病学   17185篇
神经病学   71083篇
特种医学   36102篇
外国民族医学   177篇
外科学   138342篇
综合类   28305篇
现状与发展   4篇
一般理论   264篇
预防医学   68279篇
眼科学   20993篇
药学   66762篇
  11篇
中国医学   3013篇
肿瘤学   46642篇
  2018年   7959篇
  2015年   8610篇
  2014年   12177篇
  2013年   17849篇
  2012年   24145篇
  2011年   25426篇
  2010年   15008篇
  2009年   14053篇
  2008年   23677篇
  2007年   25749篇
  2006年   25425篇
  2005年   24956篇
  2004年   24463篇
  2003年   23680篇
  2002年   22728篇
  2001年   36402篇
  2000年   36905篇
  1999年   31215篇
  1998年   9426篇
  1997年   8723篇
  1996年   8626篇
  1995年   8115篇
  1994年   7821篇
  1992年   26729篇
  1991年   26166篇
  1990年   25677篇
  1989年   24714篇
  1988年   23260篇
  1987年   22917篇
  1986年   21767篇
  1985年   21116篇
  1984年   16399篇
  1983年   14001篇
  1982年   8860篇
  1981年   8202篇
  1980年   7672篇
  1979年   16742篇
  1978年   12114篇
  1977年   10183篇
  1976年   9331篇
  1975年   10148篇
  1974年   12641篇
  1973年   12136篇
  1972年   11539篇
  1971年   10688篇
  1970年   10218篇
  1969年   9909篇
  1968年   8900篇
  1967年   8230篇
  1966年   7653篇
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
11.
Gestational trophoblastic neoplasia (GTN) patients are treated according to the eight-variable International Federation of Gynaecology and Obstetrics (FIGO) scoring system, that aims to predict first-line single-agent chemotherapy resistance. FIGO is imperfect with one-third of low-risk patients developing disease resistance to first-line single-agent chemotherapy. We aimed to generate simplified models that improve upon FIGO. Logistic regression (LR) and multilayer perceptron (MLP) modelling (n = 4191) generated six models (M1-6). M1, all eight FIGO variables (scored data); M2, all eight FIGO variables (scored and raw data); M3, nonimaging variables (scored data); M4, nonimaging variables (scored and raw data); M5, imaging variables (scored data); and M6, pretreatment hCG (raw data) + imaging variables (scored data). Performance was compared to FIGO using true and false positive rates, positive and negative predictive values, diagnostic odds ratio, receiver operating characteristic (ROC) curves, Bland-Altman calibration plots, decision curve analysis and contingency tables. M1-6 were calibrated and outperformed FIGO on true positive rate and positive predictive value. Using LR and MLP, M1, M2 and M4 generated small improvements to the ROC curve and decision curve analysis. M3, M5 and M6 matched FIGO or performed less well. Compared to FIGO, most (excluding LR M4 and MLP M5) had significant discordance in patient classification (McNemar's test P < .05); 55-112 undertreated, 46-206 overtreated. Statistical modelling yielded only small gains over FIGO performance, arising through recategorisation of treatment-resistant patients, with a significant proportion of under/overtreatment as the available data have been used a priori to allocate primary chemotherapy. Streamlining FIGO should now be the focus.  相似文献   
12.
13.
Cutaneous leiomyomas are rare benign smooth‐muscle tumors. These lesions are distinguished based on their cell of origin and are subclassified as pilar leiomyoma, angioleiomyoma, and genital‐type leiomyoma. Nipple leiomyoma is the least common genital‐type leiomyoma, arising from the dartoic muscle cell of the nipple. Histologic examination of the lesion is necessary for definitive diagnosis, and these uncommon tumors can pose a diagnostic challenge. We describe herein a series of six nipple leiomyomas with a spectrum of histologic appearances.  相似文献   
14.
15.
16.

Objective

Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.

Methods

Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.

Results

In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.

Conclusions

Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection.  相似文献   
17.
18.
19.
20.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号